Tableting lipid-based formulations for oral drug delivery: A case study with silica nanoparticle-lipid-mannitol hybrid microparticles

Journal of Pharmaceutical Sciences

Volumn 102, Issue 2, 2013, Pages 684-693

  Bremmell, Kristen E ^a   Tan, Angel ^a   Martin, Amanda ^a   Prestidge, Clive A ^a  

^a UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

Author keywords

Drug delivery systems; Dry emulsion; Lipid based formulations; Lipolysis; Oral drug delivery; Poorly soluble drug; Solid dosage form; Spray drying; Tablet

Indexed keywords

CELECOXIB; COUMARIN; COUMARIN 102; LIPID; MANNITOL; NANOPARTICLE; SILICON DIOXIDE; TRIACYLGLYCEROL LIPASE; UNCLASSIFIED DRUG;

ARTICLE; DRUG DELIVERY SYSTEM; DRUG GRANULATION; DRUG RELEASE; DRUG SOLUBILITY; EMULSION; ENCAPSULATION; IN VITRO STUDY; LIPOLYSIS; PARTICLE SIZE; PHYSICAL CHEMISTRY; TABLET COMPRESSION; TABLET DISINTEGRATION; TABLET FORMULATION; TABLET FRIABILITY; TABLET HARDNESS;

EID: 84872495688     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23406     Document Type: Article

References (36)

1. Kawakamia K, Yoshikawa T, Hayashib T, Nishihara Y, Masuda K. 2002. Microemulsion formulation for enhanced absorption of poorly soluble drugs II: In vivo study. J Control Release 81:75-82.
2. Hong J-Y, Kim J-K, Song Y-K, Park J-S, Kim C-K. 2006. A new self-emulsifying formulation of itraconazole with improved dissolution and oral absorption. J Control Release 110:332-338.
3. Boyd BJ, Khoo S-M, Whittaker DV, Davey G, Porter CJH. 2007. A lipid-based liquid crystalline matrix that provides sustained release and enhanced oral bioavailability for a model poorly water soluble drug in rats. Int J Pharm 340:52-60.
4. Porter CJH, Trevaskis NL, Charman WN. 2007. Lipids and lipid-based formulations: Optimizing the oral delivery of lipophilic drugs. Nat Rev Drug Discov 6:231-248.
5. Porter CJH, Pouton CW, Cuine JF, Charman WN. 2008. Enhancing intestinal drug solubilisation using lipid-based delivery systems. Adv Drug Deliv Rev 60:673-691.
6. Macgregor KJ, Embleton JK, Lacy JE, Perry EA, Solomon LJ, Seager H, Pouton CW. 1997. Influence of lipolysis on drug absorption from the gastro-intestinal tract. Adv Drug Del Rev 25:33-46.
7. Charman WN, Porter CJH, Mithani S, Dressman JB. 1997. Physicochemical and physiological mechanisms for the effects of food on drug absorption: The role of lipids and pH. J Pharm Sci 86:269-282.
8. Subramanian N, Ray S, Ghosal SK, Bhadra R, Priya S. 2004. Formulation and design of self-microemulsifying drug delivery systems for improved oral bioavailability of celecoxib. Biol Pharm Bull 27:1993-1999.
9. Grove M, Müllertz A, Nielsen JL, Pedersen GP. 2006. Bioavailability of seocalcitol II: Development and characterisation of self-microemulsifying drug delivery systems (SMEDDS) for oral administration containing medium and long chain triglycerides. Eur J Pharm Sci 28:233-242.
10. Takeuchi H, Sasaki H, Niwa T, Hino T, Kawashima Y, Uesugi K, Ozawa H. 1992. Design of redispersible dry emulsion as an advanced dosage form of oily drug (vitamin E nicotinate) by spray-drying technique. Drug Dev Ind Pharm 18:919-937.
11. Corveleyn S, Remon JP. 1998. Formulation of a lyophilized dry emulsion tablet for the delivery of poorly soluble drugs. Int J Pharm 166:65-74.
12. Ahmed IS, Aboul-Einien MH. 2007. In vitro and in vivo evaluation of a fast-disintegrating lyophilized dry emulsion tablet containing griseofulvin. Eur J Pharm Sci 32:58-68.
13. Gouchi-Eskandar N, Simovic S, Prestidge CA. 2012. Solid-state nanoparticle coated emulsions for encapsulation and improving the chemical stability of all-trans retinol. Int J Pharm 423:384-391.
14. Hansen T, Holm P, Schultz K. 2004. Process characteristics and compaction of spray-dried emulsions containing a drug dissolved in lipid. Int J Pharm 287:55-66.
15. Christensen KL, Pederson GP, Kristensen HG. 2001. Technical optimisation of redispersible dry emulsions. Int J Pharm 212:195-202.
16. Tan A, Simovic S, Davey AK, Rades T, Prestidge CA. 2009. Silica-lipid hybrid (SLH) microcapsules: A novel oral delivery system for poorly soluble drugs. J Control Release 134:62-70.
17. Tan A, Davey A, Prestidge CA. 2011. Silica-lipid hybrid (SLH) versus non-lipid formulations for optimising the dose-dependent oral absorption of Celecoxib. Pharm Res 28:2273-2287.
18. Simovic S, Heard P, Hui H, Song Y, Peddie F, Davey A, Lewis A, Rades T, Prestidge CA. 2009. Dry silica-lipid hybrid microcapsules engineered from submicron lipid droplets and nanoparticles as a novel delivery system for poorly soluble drugs. Mol Pharm 6:861-872.
19. Jeong SH, Takaishi Y, Fu Y, Park K. 2008. Material properties for making fast dissolving tablets by compression method. J Mater Chem 18:3527-3535.
20. Tan A, Simovic S, Davey AK, Rades T, Boyd BJ, Prestidge CA. 2010. Silica nanoparticles to control the lipase-mediated digestion of lipid-based oral delivery systems. Mol Pharm 7:522-532.
21. Lim LH, Tan A, Simovic S, Prestidge CA. 2011. Silica-lipid hybrid microcapsules: Influence of lipid and emulsifier type on in vitro performance. Int J Pharm 409:297-306.
22. Sek L, Porter CJH, Kaukonen AM, Charman WN. 2002. Evaluation of the in vitro digestion profiles of long and medium chain triglycerides and the phase behaviour of their lipolyitc products. J Pharm Pharmacol 54:29-41.
23. Naini V, Byron PR, Phillips EM. 1998. Physico-chemical stability of crystalline sugars and their spray-dried forms: Dependence upon relative humidity and suitability for use in powder inhalers. Drug Dev Ind Pharm 24:895-909.
24. Tan A, Martin A, Nguyen T-H, Boyd BJ, Prestidge CA. 2012. Hybrid nanomaterials that mimic the food effect: Controlling enzymatic digestion for enhanced oral drug absorption. Angew Chem Int 51:5475-5479.
25. Guidance for industry. 2000. Waiver of in vivo bioavailability and bioequivalence studies for immediate release solid oral dosage forms based on Biopharmaceutics Classification System. Rockville, Maryland: US Food and Drug Administration.
26. Porter CJH, Kaukonen AM, Taillardat-Bertschinger A, Boyd BJ, O'Connor JM, Edwards GA, Charman WN. 2004. Use of in vitro lipid digestion data to explain the in vivo performance of triglyceride-based oral lipid formulations of poorly water-soluble drugs: Studies with halofantrine. J Pharm Sci 93:1110-1121.
27. Zangenberg NH, Mullertz A, Kristenensen HG, Hovgaard L. 2001. A dynamic in vitro lipolysis model. II: Evaluation of the model. Eur J Pharm Sci 14:237-244.
28. Ljusberg-Wahren H, Nielsen FS, Brogard M, Troedsson E, Mullertz A. 2005. Enzymatic characterisation of lipid-based drug delivery systems. Int J Pharm 298:328-332.
29. Dahan A, Hoffman A. 2006. Use of a dynamic in vitro lipolysis model to rationalize oral formulation development for poor water soluble drugs: Correlation with in vivo data and the relationship to intraenterocyte processes in rats. Pharm Res 23:2165-2174.
30. Dahan A, Hoffman A. 2007. The effect of different lipid based formulations on the oral absorption of lipophilic drugs: the ability of in vitro lipolysis and consecutive ex vivo intestinal permeability data to predict in vivo bioavailability in rats. Eur J Pharm Biopharm 67:96-105.
31. Tsujita T, Takaichi H, Takaku T, Sawai T, Yoshida N, Hiraki J. 2007. Inhibition of lipase activities by basic polysaccharide. J Lipid Res 48:358-365.
32. Li Y, Hu M, McClements DJ. 2011. Factors effecting lipase digestibility of emulsified lipids using an in vitro digestion model: Proposal for a standardised pH-stat method. Food Chem 126:498-505.
33. Levy G, Gumtow RH. 1963. Effect of certain tablet formulation factors on dissolution rate of the active ingredient III. Tablet lubricants. J Pharm Sci 52:1139-1144.
34. Murthy KS, Samyn JC. 1977. Effect of shear mixing on in vitro drug release of capsule formulations containing lubricants. J Pharm Sci 66:1215-1219.
35. Porter CJH, Kaukonen AM, Boyd BJ, Edwards GA, Charman WN. 2004. Susceptibility to lipase-mediated digestion reduces the oral bioavailability of danzol after administration as a medium-chain lipid-based microemulsion formulation. Pharm Res 21:1405-1412.
36. Kaukonen AM, Boyd BJ, Charman WN, Porter CJH. 2004. Drug solubilisation behaviour during in-vitro digestion of suspension formulations of poorly water-soluble drugs in triglyceride lipids. Pharm Res 21:254-260.